临床药师参与对急诊室医生的工作时间分配的影响:比较分析
Renata Vesela Holis1, Beate Hennie Garcia2,3, Elin C Lehnbom3,4
1Hospital Pharmacy of North Norway Trust, Parkveien 95, Bodø 8005, Norway.
在急诊室的临床药剂师没有改变初级医生的整体工作时间分配. 与药物相关的任务仍然占医生时间的一小部分,这表明需要进一步研究药剂师的影响.
科学领域:
- 医疗保健管理
- 临床药房实践
- 紧急医疗
背景情况:
- 紧急服务部门 (ED) 处理各种患者需求,与药物相关的任务对于安全护理至关重要.
- 作为药物管理专家的临床药剂师可以提高患者的治疗效果并降低医疗费用.
- 然而,临床药剂师对ED医生工作流程的整合和影响需要进一步研究.
研究的目的:
- 评估引入临床药剂师对挪威急诊室初级医生的工作时间分配的影响.
- 具体评估与药物相关的时间分配的变化.
主要方法:
- 在挪威的三个ED中,在9个月内实施了阶梯设计.
- 为了观察初级医生的活动,使用了按活动时间计时 (WOMBAT) 的工作观察方法.
- 在临床药剂师在场和不在场期间收集数据,并比较任务时间分布.
主要成果:
- 年轻医生将8.7%的时间用于与药物相关的任务,81.0%用于非药物任务,11.6%用于备用/移动.
- 临床药剂师的引入并没有显著改变初级医生的整体工作时间分配.
- 在一个ED (ED2) 中观察到与药物相关的文档时间显著减少 (6. 1% 至 2. 5%) 和待机时间增加 (6. 1% 至 13%).
结论:
- 临床药师融入ED并没有显著改变初级医生的总体时间分配.
- 与药物相关的任务仍然占ED环境中初级医生的工作比例很小.
- 建议进一步研究临床药剂师对ED护理质量和效率的更广泛影响.
更多相关视频
09:52Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
Published on: January 15, 2017
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
相关概念视频
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
